Cargando…

Redirecting abiraterone metabolism to fine tune prostate cancer anti-androgen therapy

Abiraterone blocks androgen synthesis and prolongs survival in castration-resistant prostate cancer, which is otherwise driven by intratumoral androgen synthesis(1,2). Abiraterone is metabolized in patients to D4A, which has even greater anti-tumor activity and structural similarities to endogenous...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Zhenfei, Alyamani, Mohammad, Li, Jianneng, Rogacki, Kevin, Abazeed, Mohamed, Upadhyay, Sunil K., Balk, Steven P., Taplin, Mary-Ellen, Auchus, Richard J., Sharifi, Nima
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	2016
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5111629/ https://www.ncbi.nlm.nih.gov/pubmed/27225130 http://dx.doi.org/10.1038/nature17954

Ejemplares similares

Conversion of abiraterone to D4A drives antitumor activity in prostate cancer
por: Li, Zhenfei, et al.
Publicado: (2015)

Circulating and Intratumoral Adrenal Androgens Correlate with Response to Abiraterone in Men with Castration-Resistant Prostate Cancer
por: Mostaghel, Elahe A., et al.
Publicado: (2021)

Abiraterone Acetate: Targeting Persistent Androgen Dependence in Castration-Resistant Prostate Cancer
por: Harshman, Lauren C., et al.
Publicado: (2013)

Aberrant corticosteroid metabolism in tumor cells enables GR takeover in enzalutamide resistant prostate cancer
por: Li, Jianneng, et al.
Publicado: (2017)

Cancer-associated fibroblast-secreted glucosamine alters the androgen biosynthesis program in prostate cancer via HSD3B1 upregulation
por: Cui, Di, et al.
Publicado: (2023)

Abiraterone acetate, an inhibitor of adrenal androgen synthesis in “hormone refractory prostate cancer”
por: Goel, Arun Kumar, et al.
Publicado: (2011)

Androgen dynamics and serum PSA in patients treated with abiraterone acetate
por: Ryan, C J, et al.
Publicado: (2014)

Fine-Tuning of Optimal TCR Signaling in Tumor-Redirected CD8 T Cells by Distinct TCR Affinity-Mediated Mechanisms
por: Presotto, Danilo, et al.
Publicado: (2017)

Abiraterone Alone or in Combination With Enzalutamide in Metastatic Castration-Resistant Prostate Cancer With Rising Prostate-Specific Antigen During Enzalutamide Treatment
por: Attard, Gerhardt, et al.
Publicado: (2018)

Abiraterone acetate: oral androgen biosynthesis inhibitor for treatment of castration-resistant prostate cancer
por: Rehman, Yasser, et al.
Publicado: (2012)

The clinical efficacy and limitations of dutasteride-regulated abiraterone metabolism in abiraterone-resistant patients: a prospective single-arm clinical trial in Chinese patients
por: Liu, Ying, et al.
Publicado: (2022)

Abiraterone switches castration‐resistant prostate cancer dependency from adrenal androgens towards androgen receptor variants and glucocorticoid receptor signalling
por: Moll, J. Matthijs, et al.
Publicado: (2022)

Androgen receptor splice variants bind to constitutively open chromatin and promote abiraterone-resistant growth of prostate cancer
por: He, Yundong, et al.
Publicado: (2018)

Niclosamide enhances abiraterone treatment via inhibition of androgen receptor variants in castration resistant prostate cancer
por: Liu, Chengfei, et al.
Publicado: (2016)

Sarcopenia and change in body composition following maximal androgen suppression with abiraterone in men with castration-resistant prostate cancer
por: Pezaro, C, et al.
Publicado: (2013)

H3K9 methylation drives resistance to androgen receptor–antagonist therapy in prostate cancer
por: Baratchian, Mehdi, et al.
Publicado: (2022)

Synergistic Effect of Statins and Abiraterone Acetate on the Growth Inhibition of Neuroblastoma via Targeting Androgen Receptor
por: Hu, Zengchun, et al.
Publicado: (2021)

Androgen receptor functions in prostate cancer development and progression
por: Balk, Steven P
Publicado: (2014)

Tuning and Fine-Tuning of Synapses with Adenosine
por: Sebastião, A.M, et al.
Publicado: (2009)

Abiraterone Acetate
Publicado: (2012)

Cost-effectiveness analysis of abiraterone, docetaxel or placebo plus androgen deprivation therapy for hormone-sensitive advanced prostate cancer
por: Aguiar, Pedro Nazareth, et al.
Publicado: (2019)

Living with Advanced Hormone-Sensitive Prostate Cancer and Treatment with Abiraterone and Androgen Deprivation Therapy: The Patient, Nursing and Physician Perspective
por: Collier, Tony, et al.
Publicado: (2020)

A fuzzy fine-tuned model for COVID-19 diagnosis
por: Esmi, Nima, et al.
Publicado: (2023)

Neoadjuvant androgen deprivation therapy combined with abiraterone acetate in patients with locally advanced or metastatic prostate cancer: When to perform radical prostatectomy?
por: Xu, Ziyang, et al.
Publicado: (2022)

Association of Prostate Cancer SLCO Gene Expression with Gleason Grade and Alterations Following Androgen Deprivation Therapy
por: Alsinnawi, Mazen, et al.
Publicado: (2019)

Management of prostate cancer by targeting 3βHSD1 after enzalutamide and abiraterone treatment
por: Mei, Zejie, et al.
Publicado: (2022)

Efficacy of abiraterone acetate for high-risk hormone-naïve metastatic prostate cancer: A comparison with combined androgen blockade therapy with bicalutamide and androgen deprivation therapy alone
por: Kanao, Kent, et al.
Publicado: (2022)

Clinical effect of abiraterone acetate in Korean patients with metastatic castration-resistant prostate cancer according to duration of androgen deprivation therapy
por: Kim, Ki Bom, et al.
Publicado: (2015)

Early abiraterone acetate treatment is beneficial in Japanese castration-resistant prostate cancer after failure of primary combined androgen blockade
por: Nagai, Takashi, et al.
Publicado: (2018)

Adding abiraterone to androgen deprivation therapy in men with metastatic hormone-sensitive prostate cancer: A systematic review and meta-analysis
por: Rydzewska, Larysa H.M., et al.
Publicado: (2017)

Efficacy and safety of bipolar androgen therapy in castration-resistant prostate cancer following abiraterone or enzalutamide resistance: A systematic review
por: You, Xiangyun, et al.
Publicado: (2023)

First Line Androgen Deprivation Therapy Duration Is Associated with the Efficacy of Abiraterone Acetate Treated Metastatic Castration-Resistant Prostate Cancer after Docetaxel
por: Li, Jian-Ri, et al.
Publicado: (2017)

Low cost abiraterone
por: Barreiro, Diego Martin, et al.
Publicado: (2015)

Abiraterone-Induced Endocrinopathies
por: Decamps, Scarlett, et al.
Publicado: (2023)

Multivalent state transitions shape the intratumoral composition of small cell lung carcinoma
por: Gopal, Priyanka, et al.
Publicado: (2022)

Abiraterone acetate and docetaxel with androgen deprivation therapy in high-volume metastatic hormone-sensitive prostate cancer in China: an indirect treatment comparison and cost analysis
por: Hu, Xin, et al.
Publicado: (2019)

Fine-tuning sugar content in strawberry
por: Xing, Sinian, et al.
Publicado: (2020)

Human cytochrome P450 17A1 structures with metabolites of prostate cancer drug abiraterone reveal substrate-binding plasticity and a second binding site
por: Petrunak, Elyse M., et al.
Publicado: (2023)

A bypass mechanism of abiraterone‐resistant prostate cancer: Accumulating CYP17A1 substrates activate androgen receptor signaling
por: Moll, Jan M., et al.
Publicado: (2019)

Association of Missense Polymorphism in HSD3B1 With Outcomes Among Men With Prostate Cancer Treated With Androgen-Deprivation Therapy or Abiraterone
por: Shiota, Masaki, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_87f6675qk44m2bnqqbhkhsdgl6